📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 2.3 — Quality Overall Summary (OBX-319)

Document ID: M23
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q

2.3 Quality Overall Summary — OBX-319

This QOS summarises the Module 3 information for OBX-319, a bispecific monoclonal antibody. OBX-319 is a humanized IgG1 bispecific antibody that simultaneously engages CD19 and CD20 on the surface of B lymphocytes and is developed for subcutaneous treatment of moderate-to-severe active systemic lupus erythematosus. The molecule is a covalent, heterodimeric immunoglobulin (approximately 150 kDa) built from two distinct heavy chains and their cognate light chains; correct heavy-chain heterodimerisation is enforced by an engineered Fc interface (a knob-into-hole design stabilised by an inter-chain disulfide), and correct heavy/light-chain association is directed by an orthogonal Fab-interface strategy so that each arm retains its intended specificity. The Fc is a native, effector-competent human IgG1 that supports FcRn-mediated recycling (long serum persistence, consistent with the target-mediated drug disposition observed clinically) and Fc-dependent effector mechanisms (ADCC, CDC, ADCP) that contribute to the near-complete peripheral B-cell depletion that defines the pharmacology of the product.

The quality target product profile and the panel of critical quality attributes summarised below were derived from mechanism of action, nonclinical and clinical experience, prior platform knowledge for IgG1 antibodies, and structure/function characterisation, consistent with the enhanced product- and process-understanding principles of ICH Q11. Because therapeutic activity depends on preserved simultaneous engagement of both targets and on a consistent Fc glycosylation profile, correct bispecific assembly, dual-arm potency and effector-relevant glycation are treated as principal CQAs and are governed by the control strategy across the drug substance and drug product.

2.3.S Drug Substance

Manufactured by recombinant Chinese hamster ovary (CHO) mammalian cell culture (fed-batch).

General information. The drug substance is the humanized bispecific IgG1 antibody described above, a glycoprotein bearing conserved N-linked glycosylation at Asn297 of each CH2 domain. Nomenclature, amino-acid sequence, disulfide connectivity, the bispecific/heterodimeric architecture and general physicochemical properties (isoelectric behaviour, extinction coefficient, solubility in the formulation matrix) are described in 3.2.S.1. The molecule is a single, defined chemical entity expressed from a single recombinant CHO cell line.

Manufacture. Production uses a clonally derived recombinant CHO cell line and a two-tiered cell-bank system (master and working cell banks) established, characterised and tested for identity, purity, genetic stability of the expression construct and adventitious agents in accordance with ICH Q5A(R2), Q5B and Q5D. Upstream processing is a fed-batch suspension culture in chemically defined, animal-component-free medium, followed by clarified harvest. Downstream purification comprises Protein A affinity capture, a dedicated low-pH viral-inactivation hold, and two orthogonal polishing chromatography steps (ion-exchange/mixed-mode) selected to resolve product-related variants — in particular mispaired species, half-antibody and homodimer arising from the bispecific format — together with aggregates and host-cell impurities; the train concludes with a small-virus-retentive nanofiltration step and ultrafiltration/diafiltration into the drug-substance matrix. Sterilising-grade (0.22 µm) filtration is applied as appropriate. Viral safety is assured by two mechanistically distinct clearance operations (low-pH inactivation and virus filtration) validated per ICH Q5A(R2). Critical process parameters, in-process controls, resin/membrane lifetime and hold-time limits are defined, and the process is validated at commercial scale.

Characterisation. The molecule has been extensively characterised to confirm structure, correct bispecific assembly and biological function. Primary structure and post-translational modifications are established by intact and reduced mass spectrometry and peptide mapping, which confirm the sequence of both binding arms; correct chain pairing and the heterodimer/half-antibody/homodimer distribution are confirmed by native and reduced/non-reduced mass spectrometry and hydrophobic-interaction chromatography. Higher-order structure is assessed by spectroscopic and calorimetric methods. The N-glycosylation profile (afucosylation, galactosylation, high-mannose and sialylation) is characterised because it modulates Fc effector function relevant to potency and clearance. Biological characterisation establishes arm-specific binding to CD19 and to CD20, simultaneous (dual) engagement, B-cell binding, and Fc-mediated effector potency underpinning B-cell depletion.

Control of the drug substance. Critical quality attributes: Dual, arm-specific target binding & potency; Correct bispecific chain pairing / assembly; Aggregation (HMW) & fragmentation; N-glycosylation profile / effector attenuation; Charge variants (deamidation/isomerisation); Host-cell impurities, viral & endotoxin safety. Controlled per the drug-substance specification (3.2.S.4). The specification, set in line with ICH Q6B and informed by characterisation and clinical experience, controls identity (dual-target binding and peptide map/MS), content and potency (dual arm-binding plus a cell-based effector/depletion potency assay), purity and product-related impurities (size-exclusion chromatography for high-molecular-weight species, reduced and non-reduced CE-SDS for fragmentation and purity, imaged capillary isoelectric focusing/ion-exchange for charge variants, and a correct-pairing assay), process-related impurities (host-cell protein, residual host-cell DNA, residual Protein A), and safety (bioburden and bacterial endotoxin). All release and stability-indicating methods are validated per ICH Q2(R1). Primary and working reference standards are qualified against the clinical material and maintained under a two-tiered programme. The drug substance is stored frozen in qualified single-use containers.

Stability. The stability programme follows ICH Q5C and Q1A(R2), with long-term and accelerated storage supported by forced-degradation and stress studies that demonstrate the stability-indicating capability of the analytical panel and establish the retest period and recommended storage condition for the frozen drug substance.

2.3.P Drug Product

Sterile aqueous solution for subcutaneous injection presented in a single-use prefilled syringe and autoinjector; released and controlled per 3.2.P.5 and stored per the stability programme. Container-closure: Type I glass prefilled syringe with a coated elastomeric stopper, assembled into an autoinjector, qualified for extractables/leachables and container-closure integrity.

Composition and pharmaceutical development. The drug product is a buffered aqueous solution of OBX-319 formulated with a stabilising buffer system, a tonicity/stabiliser component and a surfactant (polysorbate) to protect the protein against interfacial and agitation stress during manufacture, shipping and device actuation. The formulation was developed to deliver the required dose in a low subcutaneous injection volume while maintaining physical and chemical stability of the bispecific (control of aggregation, fragmentation and charge-variant formation), acceptable viscosity and syringeability, and compatibility with the primary container and delivery device. Formulation, container-closure and device selection, and human-factors considerations for the autoinjector, are summarised in 3.2.P.2.

Manufacture. The drug product is manufactured by an aseptic fill-finish process comprising compounding, sterilising-grade (0.22 µm) filtration, aseptic filling of the prefilled syringe, and assembly into the autoinjector; there is no terminal sterilisation, consistent with a heat-labile biologic. Aseptic processing is validated by media fills, filter validation and container-closure integrity qualification, with defined in-process controls.

Control of the drug product. The drug-product specification (3.2.P.5) controls appearance, pH, protein content, potency, purity and product-related impurities (size-exclusion chromatography and CE-SDS), charge-variant distribution, visible and subvisible particulate matter, sterility, bacterial endotoxin, container-closure integrity and deliverable dose/extractable volume. Methods are validated per ICH Q2(R1), and acceptance criteria are justified per ICH Q6B and clinical experience. Reference standards are shared with the drug substance.

Container-closure system. The primary container is a Type I glass prefilled syringe with a coated elastomeric stopper and staked needle, assembled into a single-use autoinjector. The system is qualified for container-closure integrity, extractables and leachables, and device functional performance (break-loose/glide forces, dose delivery and activation) across the intended shelf life and use conditions.

Stability. The drug-product stability programme follows ICH Q5C and Q1A(R2) and includes long-term (refrigerated, 2-8 °C) and accelerated storage, photostability per ICH Q1B, and in-use, freeze-thaw and shipping/transport stress studies. These data establish the shelf life, storage statement and handling instructions for the marketed presentation.

2.3.R Regional

The control strategy and analytical validation follow ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q. Viral and adventitious-agent safety is addressed per ICH Q5A(R2), with the cell substrate and expression construct qualified per Q5D and Q5B; comparability across manufacturing changes and scale is evaluated per Q5E; process and product understanding and specification-setting follow Q11 and Q6B; and stability of this biotechnological product is governed by Q5C together with Q1A(R2). A product-specific risk assessment for elemental impurities (ICH Q3D) and for nitrosamines is included; residual solvents are not applicable to this aqueous biologic. The marketing application is submitted as a Biologics License Application under 21 CFR Part 601, with drug substance and drug product manufactured under applicable current Good Manufacturing Practice. Region-specific quality information, method-validation summaries, and any post-approval change-management and comparability commitments are provided in Module 3.2.R.